alpha-aminopyridine has been researched along with Gastrointestinal Stromal Neoplasm in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aimone, P; Benson, C; Brandt, U; Doi, T; Gelderblom, H; George, S; Hertle, S; Jones, RL; Le Cesne, A; Leahy, M; Renouf, DJ; Schӧffski, P; Valverde Morales, C | 1 |
| Adamson, T; Antonescu, CR; Chi, P; Condy, M; D'Angelo, SP; Dickson, MA; Gounder, M; Hwang, S; Kelly, C; Keohan, ML; Mcfadyen, CR; Movva, S; Qin, LX; Rosenbaum, E; Singer, S; Tap, WD | 1 |
| Jin, L; Kong, X; Lou, L; Quan, H; Xu, Y; Zhao, J | 1 |
| Antonescu, CR; Besmer, P; Cavnar, MJ; Cohen, NA; Crawley, MH; Dematteo, RP; Green, BL; Greer, JB; Kim, TS; Ku, AT; Pillarsetty, N; Popow, R; Rossi, F; Seifert, AM; Sorenson, EC; Veach, DR; Zeng, S | 1 |
2 trial(s) available for alpha-aminopyridine and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mental Disorders; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Sunitinib | 2020 |
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Tissue Distribution | 2019 |
2 other study(ies) available for alpha-aminopyridine and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Indoles; Interleukin-3; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Random Allocation; Sunitinib | 2014 |
Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Biopsy; Cell Survival; Disease Models, Animal; Drug Evaluation, Preclinical; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mice, Knockout; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Tumor Burden | 2014 |